Key concerns about the current state of bladder cancer: A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology

Yair Lotan, Ashish M. Kamat, Michael P. Porter, Victoria L. Robinson, Neal Shore, Michael Jewett, Paul F. Schelhammer, Ralph W deVere White, Diane Quale, Cheryl T. Lee

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Bladder cancer is the fifth most common cancer in the United States and, on a per capita basis, is the most expensive cancer from diagnosis to death. Unfortunately, National Cancer Institute funding for bladder cancer is quite low when compared with other common malignancies. Limited funding has stifled research opportunities for new and established investigators, ultimately encouraging them to redirect research efforts to other organ sites.Waning interest of scientists has further fueled the cycle of modest funding for bladder cancer. One important consequence of this has been a lack of scientific advancement in the field. Patient advocates have decidedly advanced research efforts in many cancer sites. Breast, prostate, pancreatic, and ovarian cancer advocates have organized highly successful campaigns to lobby the federal government and the medical community to devote increased attention and funding to understudied malignancies and to conduct relevant studies to better understand the therapy, diagnosis, and prevention of these diseases. Bladder cancer survivors have lacked a coordinated advocacy voice until recently. A concerted effort to align bladder cancer advocates, clinicians, and urologic organizations is essential to define the greatest needs in bladder cancer and to develop related solutions. This position paper represents a collaborative discussion to define the most concerning trends and greatest needs in the field of bladder cancer as outlined by the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

Original languageEnglish (US)
Pages (from-to)4096-4103
Number of pages8
JournalCancer
Volume115
Issue number18
DOIs
StatePublished - Sep 15 2009

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Research
Federal Government
National Cancer Institute (U.S.)
Pancreatic Neoplasms
Ovarian Neoplasms
Survivors
Prostatic Neoplasms
Research Personnel
Organizations
Breast Neoplasms

Keywords

  • Advocacy
  • Bladder cancer
  • Concerns
  • Funding

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Key concerns about the current state of bladder cancer : A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. / Lotan, Yair; Kamat, Ashish M.; Porter, Michael P.; Robinson, Victoria L.; Shore, Neal; Jewett, Michael; Schelhammer, Paul F.; deVere White, Ralph W; Quale, Diane; Lee, Cheryl T.

In: Cancer, Vol. 115, No. 18, 15.09.2009, p. 4096-4103.

Research output: Contribution to journalArticle

Lotan, Yair ; Kamat, Ashish M. ; Porter, Michael P. ; Robinson, Victoria L. ; Shore, Neal ; Jewett, Michael ; Schelhammer, Paul F. ; deVere White, Ralph W ; Quale, Diane ; Lee, Cheryl T. / Key concerns about the current state of bladder cancer : A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. In: Cancer. 2009 ; Vol. 115, No. 18. pp. 4096-4103.
@article{f133881f5a394ef4ba49490eebe94fb6,
title = "Key concerns about the current state of bladder cancer: A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology",
abstract = "Bladder cancer is the fifth most common cancer in the United States and, on a per capita basis, is the most expensive cancer from diagnosis to death. Unfortunately, National Cancer Institute funding for bladder cancer is quite low when compared with other common malignancies. Limited funding has stifled research opportunities for new and established investigators, ultimately encouraging them to redirect research efforts to other organ sites.Waning interest of scientists has further fueled the cycle of modest funding for bladder cancer. One important consequence of this has been a lack of scientific advancement in the field. Patient advocates have decidedly advanced research efforts in many cancer sites. Breast, prostate, pancreatic, and ovarian cancer advocates have organized highly successful campaigns to lobby the federal government and the medical community to devote increased attention and funding to understudied malignancies and to conduct relevant studies to better understand the therapy, diagnosis, and prevention of these diseases. Bladder cancer survivors have lacked a coordinated advocacy voice until recently. A concerted effort to align bladder cancer advocates, clinicians, and urologic organizations is essential to define the greatest needs in bladder cancer and to develop related solutions. This position paper represents a collaborative discussion to define the most concerning trends and greatest needs in the field of bladder cancer as outlined by the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.",
keywords = "Advocacy, Bladder cancer, Concerns, Funding",
author = "Yair Lotan and Kamat, {Ashish M.} and Porter, {Michael P.} and Robinson, {Victoria L.} and Neal Shore and Michael Jewett and Schelhammer, {Paul F.} and {deVere White}, {Ralph W} and Diane Quale and Lee, {Cheryl T.}",
year = "2009",
month = "9",
day = "15",
doi = "10.1002/cncr.24463",
language = "English (US)",
volume = "115",
pages = "4096--4103",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",

}

TY - JOUR

T1 - Key concerns about the current state of bladder cancer

T2 - A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology

AU - Lotan, Yair

AU - Kamat, Ashish M.

AU - Porter, Michael P.

AU - Robinson, Victoria L.

AU - Shore, Neal

AU - Jewett, Michael

AU - Schelhammer, Paul F.

AU - deVere White, Ralph W

AU - Quale, Diane

AU - Lee, Cheryl T.

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Bladder cancer is the fifth most common cancer in the United States and, on a per capita basis, is the most expensive cancer from diagnosis to death. Unfortunately, National Cancer Institute funding for bladder cancer is quite low when compared with other common malignancies. Limited funding has stifled research opportunities for new and established investigators, ultimately encouraging them to redirect research efforts to other organ sites.Waning interest of scientists has further fueled the cycle of modest funding for bladder cancer. One important consequence of this has been a lack of scientific advancement in the field. Patient advocates have decidedly advanced research efforts in many cancer sites. Breast, prostate, pancreatic, and ovarian cancer advocates have organized highly successful campaigns to lobby the federal government and the medical community to devote increased attention and funding to understudied malignancies and to conduct relevant studies to better understand the therapy, diagnosis, and prevention of these diseases. Bladder cancer survivors have lacked a coordinated advocacy voice until recently. A concerted effort to align bladder cancer advocates, clinicians, and urologic organizations is essential to define the greatest needs in bladder cancer and to develop related solutions. This position paper represents a collaborative discussion to define the most concerning trends and greatest needs in the field of bladder cancer as outlined by the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

AB - Bladder cancer is the fifth most common cancer in the United States and, on a per capita basis, is the most expensive cancer from diagnosis to death. Unfortunately, National Cancer Institute funding for bladder cancer is quite low when compared with other common malignancies. Limited funding has stifled research opportunities for new and established investigators, ultimately encouraging them to redirect research efforts to other organ sites.Waning interest of scientists has further fueled the cycle of modest funding for bladder cancer. One important consequence of this has been a lack of scientific advancement in the field. Patient advocates have decidedly advanced research efforts in many cancer sites. Breast, prostate, pancreatic, and ovarian cancer advocates have organized highly successful campaigns to lobby the federal government and the medical community to devote increased attention and funding to understudied malignancies and to conduct relevant studies to better understand the therapy, diagnosis, and prevention of these diseases. Bladder cancer survivors have lacked a coordinated advocacy voice until recently. A concerted effort to align bladder cancer advocates, clinicians, and urologic organizations is essential to define the greatest needs in bladder cancer and to develop related solutions. This position paper represents a collaborative discussion to define the most concerning trends and greatest needs in the field of bladder cancer as outlined by the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

KW - Advocacy

KW - Bladder cancer

KW - Concerns

KW - Funding

UR - http://www.scopus.com/inward/record.url?scp=70149120096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149120096&partnerID=8YFLogxK

U2 - 10.1002/cncr.24463

DO - 10.1002/cncr.24463

M3 - Article

C2 - 19536899

AN - SCOPUS:70149120096

VL - 115

SP - 4096

EP - 4103

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 18

ER -